Enliven Therapeutics, Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. Enliven is a clinical-stage oncology biotechnology company with no approved products or revenue. Its lead candidates, ELVN-001 and ELVN-002, were in Phase 1 trials for CML and HER2-altered solid tumors, respectively; the company also reported nominating a third candidate.
Financial performance
Amounts are in millions, except per-share data. The company reported no revenue; margins are therefore not meaningful.
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Research and development | $15.2 | $7.9 | $27.1 | $15.0 |
| General and administrative | $5.0 | $1.1 | $9.5 | $2.7 |
| Total operating expenses | $20.1 | $9.0 | $36.6 | $17.7 |
| Net loss | $16.7 | $8.9 | $31.4 | $17.6 |
| Net loss per share, basic and diluted | $0.41 | $2.86 | $1.05 | $5.87 |
| Interest income | $3.4 | $0.1 | $5.1 | $0.1 |
At June 30, cash and cash equivalents were $125.7 million and marketable securities were $152.2 million, totaling approximately $277.9 million. Current assets were $283.2 million versus current liabilities of $9.1 million; total liabilities were $9.5 million. The company reported no debt outstanding. Accumulated deficit was $114.3 million.
For the first six months, operating cash used was $32.9 million, investing cash used was $151.5 million—principally purchases of marketable securities—and financing provided $234.6 million. Financing included $161.4 million net from the pre-merger financing and $73.1 million net cash acquired in the reverse recapitalization.
Material changes and notable transactions
- Q2 operating expenses more than doubled year over year. R&D increased $7.3 million, primarily from clinical-trial and other external costs, personnel costs, and stock-based compensation. G&A increased $3.9 million, including higher stock compensation and professional services.
- Higher interest income reflected increased interest rates and investment balances. The lower reported loss per share versus 2022 reflects a substantially larger weighted-average share count after the merger, not improved profitability.
- The February 23, 2023 merger with Former Enliven was accounted for as a reverse recapitalization. Former Enliven was the accounting acquirer; its preferred stock converted to common stock. The related financing raised $164.5 million gross before the merger.
- Stock-based compensation was $4.2 million in Q2 and $6.5 million for the first half. First-half G&A included $1.3 million of accelerated option-vesting expense related to the merger.
- The company filed a $400 million shelf registration statement, effective July 3, 2023, and established a $200 million at-the-market stock offering. No ATM shares had been sold as of the filing. The filing also noted that approximately 18 million shares could become saleable after merger-related lockups expire.
Outlook, risks, and contingencies
- Management expects operating losses and negative operating cash flows to continue as it develops its pipeline. It stated that available cash, cash equivalents, and marketable securities should fund planned operating expenses and capital needs for at least 12 months from the filing date; elsewhere, the risk factors said merger-related cash was expected to fund operations into early 2026. These are estimates dependent on the operating plan and assumptions.
- Management expects R&D and G&A spending to rise as trials and research advance, the organization grows, and public-company costs continue. The filing provides no product revenue or profitability guidance.
- Key risks include clinical and regulatory failure or delay, patient enrollment and competition, reliance on third parties for trials and manufacturing, and the need for substantial additional financing. Pharmaron had previously experienced COVID-related delays that caused minor preclinical delays; the company also cited potential supplier and geopolitical exposure associated with reliance on providers in China.
- The company reported no material current litigation. A merger-related shareholder complaint was voluntarily dismissed in January 2023 after supplemental disclosures; an immaterial mootness fee was paid. The company reported no material business disruption or asset impairment from macroeconomic and geopolitical developments to date.
- Management concluded that disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 2023.
Important facts for investors to verify
- Review clinical-trial progress and forthcoming data for ELVN-001 and ELVN-002, and the development status of the newly nominated candidate.
- Assess the cash runway assumptions, ongoing operating cash use, and whether additional financing will be needed; confirm any subsequent ATM sales or other capital raises.
- Track dilution and potential share supply from outstanding equity awards, merger-related lockup expirations, and the ATM facility.
- Monitor rising R&D and G&A costs, including stock-based compensation, against development milestones and any changes in management’s plans.
- Evaluate dependence on external clinical and manufacturing providers, including supply continuity and enrollment risks.